NEW YORK – This past year the impact of the COVID-19 pandemic on cancer care and clinical trials was at the forefront of readers' minds as researchers and regulators strove to adjust protocols so some studies could continue despite lockdown rules and safety measures, and as oncologists made greater use of telemedicine to limit unnecessary exposure to patients.